Manufacturable Process of a Novel EGFR Inhibitor (Larotinib) for the Treatment of ESCC-Reference-Cited by-同舟云学术

Manufacturable Process of a Novel EGFR Inhibitor (Larotinib) for the Treatment of ESCC

Published:2022-05-09 Issue:5 Volume:26 Page:1470-1485
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Zhang Weihong¹^ORCID,Su Zhiming²,Liu Haiwang²^ORCID,Zhang Yingjun²,Ye Weiliang²,Peng Dahua²,Xie Hongpeng²,Peng Hongtao²,Peng Zhihong¹,Dong Wanrong¹^ORCID,An Delie¹

Affiliation:

1. State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China

2. Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00059

Reference44 articles.

1. Improved Synthesis of Gefitinib and Erlotinib Hydrochloride‐ Anticancer Agents

2. The epidermal growth factor receptor ligands at a glance

3. Concise, gram-scale synthesis of furo[2,3-b]pyridines with functional handles for chemoselective cross-coupling

4. Anderson, M.; Attar, R.; Diem, M.; Hyun, L.; Jacobs, S.; King, A.; Klein, D.; Moores, S.; O’Neil, K.; Picha, K. EGFR and c-Met-fibronectin Type III Domain Binding Molecules. AU2020267284A12020.

5. Theoretical evaluation of EGFR kinase inhibition and toxicity of di-indol-3-yl disulphides with anti-cancer potency

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous Flow Synthesis of a Key Intermediate Common to Gefitinib and Larotinib;Organic Process Research & Development;2024-02-20